Cockrell Group to Represent AxoGen Investor Relations

ATLANTA--(BUSINESS WIRE)-- The Cockrell Group, a leading healthcare-focused investor relations firm, today announced that it has been engaged by AxoGen, Inc. (OTCBB: AXGN), a regenerative medicine company focused on the development and commercialization of technologies for peripheral nerve reconstruction and regeneration.

“Our primary objective will be to increase AxoGen’s awareness among targeted portfolio managers and equity analysts in the investment community,” said Rich Cockrell, President of the Cockrell Group. “Our firm actively searches for investment ideas that are innovative technologies in healthcare. AxoGen’s technologies involving the regeneration and reconstruction of peripheral nerves are unique within regenerative medicine and I am excited about the opportunity our firm has in introducing the Company to investors.”

"Rich came highly recommended by several healthcare analysts and industry professionals,” said Greg Freitag, Chief Financial Officer of AxoGen. “I am confident that his firm will execute well on behalf of AxoGen shareholders and we look forward to working with the Cockrell Group."

About The Cockrell Group

The Cockrell Group, Inc. is a strategic investor relations and corporate access firm focused on small-to-midcap companies in healthcare. It aligns a company's strategic goals to an institution's investment thesis and fundamentals to create a sound, long-term investment objective. The company also advises companies in various areas, including private and pre-IPO activity, mergers and acquisitions, bankruptcy, executive transitions, activist shareholders, hostile takeovers, and downsizing, as well as manages events.

About AxoGen, Inc.

AxoGen, Inc. (“AxoGen”) is a regenerative medicine company focused on the development and commercialization of technologies for peripheral nerve reconstruction and regeneration. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes the Avance® Nerve Graft which AxoGen believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed). AxoGen’s portfolio also includes the AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and the AxoGuard® Nerve Protector that protects nerves during the body’s healing process after surgery. AxoGen is bringing the science of nerve repair to life with over 6,000 surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen (formerly known as LecTec Corporation) is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. AxoGen’s common stock currently trades on the Over-the-Counter Bulletin Board under the symbol “AXGN”.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

COCKRELL GROUP
Rich Cockrell, 404-942-3369
President
[email protected]
cockrellgroup.com
or
AxoGen, Inc.
Greg Freitag, 386-462-6856
Chief Financial Officer

KEYWORDS:   United States  North America  Georgia

INDUSTRY KEYWORDS:   Surgery  Health  Medical Devices  Communications  Public Relations/Investor Relations

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.